Skip to content
2000
Volume 25, Issue 14
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2D), which often leads to diabetic kidney disease (DKD). Traditional therapies, including renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors, are effective in slowing CKD progression. However, these approaches are insufficient to comprehensively inhibit mineralocorticoid receptor (MR) overactivation in the kidneys, which remains a significant driver of inflammation, fibrosis, and oxidative stress. These pathological processes accelerate kidney damage and cardiovascular complications. Finerenone-a nonsteroidal mineralocorticoid receptor antagonist-represents a new frontier in renal protection. Unlike steroidal mineralocorticoid antagonists (MRAs), finerenone offers a more selective MR blockade, reducing kidney inflammation and fibrosis without significantly raising serum potassium levels. Landmark trials have demonstrated the ability of finerenone to significantly reduce kidney and cardiovascular events in patients with T2D and CKD. Clinical evidence has highlighted finerenone as an effective option for slowing DKD progression while maintaining a favorable safety profile. Based on these findings, recent guidelines have incorporated finerenone as a recommended therapy for patients with T2D and CKD, emphasizing its role in reducing both renal and cardiovascular risks. This review provides a comprehensive overview of the available data to offer a deeper understanding of the potential of finerenone to transform CKD management for T2D patients.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303350851241021105850
2025-01-08
2025-12-15

  • From This Site

    /content/journals/emiddt/10.2174/0118715303350851241021105850
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/25/14/EMIDDT-25-14-01.html?itemId=/content/journals/emiddt/10.2174/0118715303350851241021105850&mimeType=html&fmt=ahah

References

  1. GrossJ.L. de AzevedoM.J. SilveiroS.P. CananiL.H. CaramoriM.L. ZelmanovitzT. Diabetic nephropathy: Diagnosis, prevention, and treatment.Diabetes Care200528116417610.2337/diacare.28.1.16415616252
     [Google Scholar]
  2. DekkersC.C.J. GansevoortR.T. HeerspinkH.J.L. New diabetes therapies and diabetic kidney disease progression: The role of SGLT-2 inhibitors.Curr. Diab. Rep.20181852710.1007/s11892‑018‑0992‑629589183
     [Google Scholar]
  3. van BaarM.J.B. van der AartA.B. HoogenbergK. JolesJ.A. HeerspinkH.J.L. van RaalteD.H. The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists.Ther. Adv. Endocrinol. Metab.201910204201881986539810.1177/204201881986539831384419
     [Google Scholar]
  4. DasguptaI. BanerjeeD. ChowdhuryT.A. DeP. WahbaM. BainS. FrankelA. FogartyD. PokrajacA. WinocourP.H. Association of british clinical diabetologists (ABCD) and renal association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease.Br. J. Diabetes201717416016410.15277/bjd.2017.152
     [Google Scholar]
  5. RichS.S. Genetic contribution to risk for diabetic kidney disease.Clin. J. Am. Soc. Nephrol.20181381135113710.2215/CJN.0724061830012628
     [Google Scholar]
  6. BansalN. KatzR. Robinson-CohenC. OddenM.C. DalrympleL. ShlipakM.G. SarnakM.J. SiscovickD.S. ZelnickL. PsatyB.M. KestenbaumB. CorreaA. AfkarianM. YoungB. de BoerI.H. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease.JAMA Cardiol.20172331431810.1001/jamacardio.2016.465228002548
     [Google Scholar]
  7. AfkarianM. SachsM.C. KestenbaumB. HirschI.B. TuttleK.R. HimmelfarbJ. de BoerI.H. Kidney disease and increased mortality risk in type 2 diabetes.J. Am. Soc. Nephrol.201324230230810.1681/ASN.201207071823362314
     [Google Scholar]
  8. KitamuraH. TanakaS. HiyamutaH. ShimamotoS. TsuruyaK. NakanoT. KitazonoT. Cardiovascular risk factor burden and treatment control in patients with chronic kidney disease: A cross-sectional study.J. Atheroscler. Thromb.20233091210128810.5551/jat.6389136596531
     [Google Scholar]
  9. FosterM.C. RawlingsA.M. MarrettE. NeffD. WillisK. InkerL.A. CoreshJ. SelvinE. Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States.Am. Heart J.20131661150156.e110.1016/j.ahj.2013.03.01623816034
     [Google Scholar]
  10. LeonB.M. MaddoxT.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.World J. Diabetes20156131246125810.4239/wjd.v6.i13.124626468341
     [Google Scholar]
  11. Dal CantoE. CerielloA. RydénL. FerriniM. HansenT.B. SchnellO. StandlE. BeulensJ.W.J. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications.Eur. J. Prev. Cardiol.201926Suppl.253210.1177/204748731987837131722562
     [Google Scholar]
  12. HeerspinkH.J.L. KarasikA. ThuressonM. Melzer-CohenC. ChodickG. KhuntiK. WildingJ.P.H. Garcia RodriguezL.A. Cea-SorianoL. KohsakaS. NicolucciA. LucisanoG. LinF.J. WangC.Y. WittbrodtE. FeniciP. KosiborodM. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.Lancet Diabetes Endocrinol.202081273510.1016/S2213‑8587(19)30384‑531862149
     [Google Scholar]
  13. GiuglianoD. EspositoK. Class effect for SGLT-2 inhibitors: a tale of 9 drugs.Cardiovasc. Diabetol.20191819410.1186/s12933‑019‑0899‑931337395
     [Google Scholar]
  14. PerkovicV. JardineM.J. NealB. BompointS. HeerspinkH.J.L. CharytanD.M. EdwardsR. AgarwalR. BakrisG. BullS. CannonC.P. CapuanoG. ChuP.L. de ZeeuwD. GreeneT. LevinA. PollockC. WheelerD.C. YavinY. ZhangH. ZinmanB. MeiningerG. BrennerB.M. MahaffeyK.W. CREDENCE Trial Investigators Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N. Engl. J. Med.2019380242295230610.1056/NEJMoa181174430990260
     [Google Scholar]
  15. AgarwalR. JosephA. AnkerS.D. FilippatosG. RossingP. RuilopeL.M. PittB. KolkhofP. ScottC. LawatscheckR. WilsonD.J. BakrisG.L. Hyperkalemia risk with finerenone: Results from the FIDELIO-DKD trial.J. Am. Soc. Nephrol.202233122523710.1681/ASN.202107094234732509
     [Google Scholar]
  16. BakrisG.L. AgarwalR. ChanJ.C. CooperM.E. GansevoortR.T. HallerH. RemuzziG. RossingP. SchmiederR.E. NowackC. KolkhofP. JosephA. PieperA. Kimmeskamp-KirschbaumN. RuilopeL.M. Effect of finerenone on albuminuria in patients with diabetic nephropathy.JAMA2015314988489410.1001/jama.2015.1008126325557
     [Google Scholar]
  17. BakrisG.L. AgarwalR. AnkerS.D. PittB. RuilopeL.M. RossingP. KolkhofP. NowackC. SchloemerP. JosephA. FilippatosG. FIDELIO-DKD Investigators Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N. Engl. J. Med.2020383232219222910.1056/NEJMoa202584533264825
     [Google Scholar]
  18. BauersachsJ. JaisserF. TotoR. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.Hypertension201565225726310.1161/HYPERTENSIONAHA.114.0448825368026
     [Google Scholar]
  19. PanizoS. Martínez-AriasL. Alonso-MontesC. CannataP. Martín-CarroB. Fernández-MartínJ.L. Naves-DíazM. Carrillo-LópezN. Cannata-AndíaJ.B. Fibrosis in chronic kidney disease: Pathogenesis and consequences.Int. J. Mol. Sci.202122140810.3390/ijms2201040833401711
     [Google Scholar]
  20. ChaudhuriA. GhanimH. AroraP. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials.Diabetes Obes. Metab.202224336537610.1111/dom.1460134779091
     [Google Scholar]
  21. TeschG.H. YoungM.J. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis.Front. Pharmacol.2017831310.3389/fphar.2017.0031328611666
     [Google Scholar]
  22. Solis-HerreraC. TriplittC. Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.Diabetes Obes. Metab.202426241743010.1111/dom.1532737885354
     [Google Scholar]
  23. BuonafineM. BonnardB. JaisserF. Mineralocorticoid receptor and cardiovascular disease.Am. J. Hypertens.201831111165117410.1093/ajh/hpy12030192914
     [Google Scholar]
  24. Gomez-SanchezE. Gomez-SanchezC.E. The multifaceted mineralocorticoid receptor.Compr. Physiol.20144396599410.1002/cphy.c13004424944027
     [Google Scholar]
  25. AgarwalR. KolkhofP. BakrisG. BauersachsJ. HallerH. WadaT. ZannadF. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.Eur. Heart J.202142215216110.1093/eurheartj/ehaa73633099609
     [Google Scholar]
  26. PittB. ZannadF. RemmeW.J. CodyR. CastaigneA. PerezA. PalenskyJ. WittesJ. Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure.N. Engl. J. Med.19993411070971710.1056/NEJM19990902341100110471456
     [Google Scholar]
  27. MoralesJ. PalmerB.F. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.Postgrad. Med.2024136211111910.1080/00325481.2024.231657238344772
     [Google Scholar]
  28. PittB. PfefferM.A. AssmannS.F. BoineauR. AnandI.S. ClaggettB. ClausellN. DesaiA.S. DiazR. FlegJ.L. GordeevI. HartyB. HeitnerJ.F. KenwoodC.T. LewisE.F. O’MearaE. ProbstfieldJ.L. ShaburishviliT. ShahS.J. SolomonS.D. SweitzerN.K. YangS. McKinlayS.M. TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction.N. Engl. J. Med.2014370151383139210.1056/NEJMoa131373124716680
     [Google Scholar]
  29. KDIGO Executive Committee. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney disease.2024
     [Google Scholar]
  30. de BoerI.H. KhuntiK. SaduskyT. TuttleK.R. NeumillerJ.J. RheeC.M. RosasS.E. RossingP. BakrisG. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).Diabetes Care202245123075309010.2337/dci22‑002736189689
     [Google Scholar]
  31. ElSayedN.A. AleppoG. ArodaV.R. BannuruR.R. BrownF.M. BruemmerD. CollinsB.S. DasS.R. HilliardM.E. IsaacsD. JohnsonE.L. KahanS. KhuntiK. KosiborodM. LeonJ. LyonsS.K. PerryM.L. PrahaladP. PratleyR.E. SeleyJ.J. StantonR.C. GabbayR.A. on behalf of the American Diabetes Association Cardiovascular disease and risk management: Standards of care in diabetes.Diabetes Care202346Suppl. 1S158S19010.2337/dc23‑S01036507632
     [Google Scholar]
  32. ShaikhA. RayJ. CampbellK.N. Role of finerenone in the treatment of diabetic kidney disease: Patient selection and clinical perspectives.Ther. Clin. Risk Manag.20221875376010.2147/TCRM.S32591635937973
     [Google Scholar]
  33. JaisserF. FarmanN. Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology.Pharmacol. Rev.2016681497510.1124/pr.115.01110626668301
     [Google Scholar]
  34. VermaA. VaidyaA. SubudhiS. WaikarS.S. Aldosterone in chronic kidney disease and renal outcomes.Eur. Heart J.202243383781379110.1093/eurheartj/ehac35236219773
     [Google Scholar]
  35. PalanisamyS. Funes HernandezM. ChangT.I. MahaffeyK.W. Cardiovascular and renal outcomes with finerenone, a selective mineralocorticoid receptor antagonist.Cardiol. Ther.202211333735410.1007/s40119‑022‑00269‑335737275
     [Google Scholar]
  36. BakrisG.L. JaisserF. Aldosterone excess and cardiorenal risk: More common than appreciated.Eur. Heart J.202243383792379310.1093/eurheartj/ehac41036219774
     [Google Scholar]
  37. LotherA. Mineralocorticoid receptors.Circ. Res.2020127335435610.1161/CIRCRESAHA.120.31742432673533
     [Google Scholar]
  38. BeldenZ. DeiuliisJ.A. DobreM. RajagopalanS. The role of the mineralocorticoid receptor in inflammation: Focus on kidney and vasculature.Am. J. Nephrol.201746429831410.1159/00048065229017166
     [Google Scholar]
  39. Barrera-ChimalJ. GirerdS. JaisserF. Mineralocorticoid receptor antagonists and kidney diseases: Pathophysiological basis.Kidney Int.201996230231910.1016/j.kint.2019.02.03031133455
     [Google Scholar]
  40. LiuW. YuS. Nonsteroidal mineralocorticoid receptor antagonist eliciting cardiorenal protection is a new option for patients with chronic kidney disease.Kidney Dis.202391122510.1159/00052806636756081
     [Google Scholar]
  41. KintscherU. BakrisG.L. KolkhofP. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.Br. J. Pharmacol.2022179133220323410.1111/bph.1574734811750
     [Google Scholar]
  42. LermaE. WhiteW.B. BakrisG. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.Postgrad. Med.2023135322423310.1080/00325481.2022.206059835392754
     [Google Scholar]
  43. LavallD. JacobsN. MahfoudF. KolkhofP. BöhmM. LaufsU. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.Biochem. Pharmacol.201916817318310.1016/j.bcp.2019.07.00131283930
     [Google Scholar]
  44. LvR. XuL. CheL. LiuS. WangY. DongB. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.Front. Endocrinol. (Lausanne)202314112569310.3389/fendo.2023.112569336860374
     [Google Scholar]
  45. González-JuanateyJ.R. GórrizJ.L. OrtizA. ValleA. SolerM.J. FacilaL. Cardiorenal benefits of finerenone: protecting kidney and heart.Ann. Med.202355150251310.1080/07853890.2023.217111036719097
     [Google Scholar]
  46. MassyZ.A. DruekeT.B. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations.Kidney Int. Rep.2024992608261810.1016/j.ekir.2024.05.03339291205
     [Google Scholar]
  47. PittB. FilippatosG. AgarwalR. AnkerS.D. BakrisG.L. RossingP. JosephA. KolkhofP. NowackC. SchloemerP. RuilopeL.M. FIGARO-DKD Investigators Cardiovascular events with finerenone in kidney disease and type 2 diabetes.N. Engl. J. Med.2021385242252226310.1056/NEJMoa211095634449181
     [Google Scholar]
  48. RuilopeL.M. PittB. AnkerS.D. RossingP. KovesdyC.P. Pecoits-FilhoR. PergolaP. JosephA. LageA. MentenichN. ScheererM.F. BakrisG.L. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.Nephrol. Dial. Transplant.202338237238310.1093/ndt/gfac15735451488
     [Google Scholar]
  49. AgarwalR. FilippatosG. PittB. AnkerS.D. RossingP. JosephA. KolkhofP. NowackC. GebelM. RuilopeL.M. BakrisG.L. FIDELIO-DKD and FIGARO-DKD investigators Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.Eur. Heart J.202243647448410.1093/eurheartj/ehab77735023547
     [Google Scholar]
  50. PittB. KoberL. PonikowskiP. GheorghiadeM. FilippatosG. KrumH. NowackC. KolkhofP. KimS.Y. ZannadF. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.Eur. Heart J.201334312453246310.1093/eurheartj/eht18723713082
     [Google Scholar]
  51. FilippatosG. AnkerS.D. BöhmM. GheorghiadeM. KøberL. KrumH. MaggioniA.P. PonikowskiP. VoorsA.A. ZannadF. KimS.Y. NowackC. PalomboG. KolkhofP. Kimmeskamp-KirschbaumN. PieperA. PittB. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.Eur. Heart J.201637272105211410.1093/eurheartj/ehw13227130705
     [Google Scholar]
  52. ZhengY. MaS. HuangQ. FangY. TanH. ChenY. LiC. Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease.Kidney Blood Press. Res.202247421922810.1159/00052190835034019
     [Google Scholar]
  53. KolkhofP. DelbeckM. KretschmerA. SteinkeW. HartmannE. BärfackerL. EitnerF. Albrecht-KüpperB. SchäferS. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.J. Cardiovasc. Pharmacol.2014641697810.1097/FJC.000000000000009124621652
     [Google Scholar]
  54. AmazitL. Le BillanF. KolkhofP. LamribetK. ViengchareunS. FayM.R. KhanJ.A. HillischA. LombèsM. Rafestin-OblinM.E. FagartJ. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1.J. Biol. Chem.201529036218762188910.1074/jbc.M115.65795726203193
     [Google Scholar]
  55. SchwenkM.H. HirschJ.S. BombackA.S. Aldosterone blockade in CKD: Emphasis on pharmacology.Adv. Chronic Kidney Dis.201522212313210.1053/j.ackd.2014.08.00325704349
     [Google Scholar]
  56. GerischM. HeinigR. EngelenA. LangD. KolkhofP. RadtkeM. PlatzekJ. LovisK. RohdeG. SchwarzT. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro.Drug Metab. Dispos.201846111546155510.1124/dmd.118.08333730171161
     [Google Scholar]
  57. HeinigR. Kimmeskamp-KirschbaumN. HalabiA. LentiniS. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment.Clin. Pharmacol. Drug Dev.20165648850110.1002/cpdd.26327431783
     [Google Scholar]
  58. AgarwalR. RossignolP. RomeroA. GarzaD. MayoM.R. WarrenS. MaJ. WhiteW.B. WilliamsB. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial.Lancet2019394102081540155010.1016/S0140‑6736(19)32135‑X31533906
     [Google Scholar]
  59. GruneJ. BeyhoffN. SmeirE. ChudekR. BlumrichA. BanZ. BrixS. BetzI.R. SchuppM. Foryst-LudwigA. KlopfleischR. StawowyP. HoutmanR. KolkhofP. KintscherU. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity.Hypertension201871459960810.1161/HYPERTENSIONAHA.117.1036029437893
     [Google Scholar]
  60. Barrera-ChimalJ. KolkhofP. Lima-PosadaI. AlexandreJ. RossignolP. JaisserF. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics.Expert Opin. Investig. Drugs202130111141115710.1080/13543784.2021.200284434758679
     [Google Scholar]
  61. ZhuS. LiJ. ZhaoX. Comparative risk of new-onset hyperkalemia for antihypertensive drugs in patients with diabetic nephropathy: A bayesian network meta-analysis.Int. J. Clin. Pract.2021758e1394010.1111/ijcp.1394033332696
     [Google Scholar]
  62. AgarwalR. PittB. PalmerB.F. KovesdyC.P. BurgessE. FilippatosG. MałyszkoJ. RuilopeL.M. RossignolP. RossingP. Pecoits-FilhoR. AnkerS.D. JosephA. LawatscheckR. WilsonD. GebelM. BakrisG.L. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.Clin. Kidney J.202316229330210.1093/ckj/sfac23436864892
     [Google Scholar]
  63. PeiH. WangW. ZhaoD. WangL. SuG.H. ZhaoZ. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure.Medicine (Baltimore)20189716e025410.1097/MD.000000000001025429668577
     [Google Scholar]
  64. PittB. Pedro FerreiraJ. ZannadF. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives.Eur. Heart J. Cardiovasc. Pharmacother.201731485710.1093/ehjcvp/pvw01627530337
     [Google Scholar]
  65. PatouliasD. KatsimardouA. SviggouA. KordalisV. AidinisA. ImprialosK. StavropoulosK. KaragiannisA. PapadopoulosC. DoumasM. Major adverse events with the use of finerenone in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcome trials.J. Hypertens.202240Suppl. 1e158e15910.1097/01.hjh.0000836960.12035.10
     [Google Scholar]
  66. RiegT. VallonV. SausbierM. SausbierU. KaisslingB. RuthP. OsswaldH. The role of the BK channel in potassium homeostasis and flow-induced renal potassium excretion.Kidney Int.200772556657310.1038/sj.ki.500236917579662
     [Google Scholar]
  67. SarnowskiA. GamaR.M. DawsonA. MasonH. BanerjeeD. Hyperkalemia in chronic kidney disease: Links, risks and management.Int. J. Nephrol. Renovasc. Dis.20221521522810.2147/IJNRD.S32646435942480
     [Google Scholar]
  68. FountainJ.H. KaurJ. LappinS.L. Physiology, Renin Angiotensin System.StatPearls2023
     [Google Scholar]
  69. PalmerB.F. CleggD.J. Physiology and pathophysiology of potassium homeostasis: Core curriculum 2019.Am. J. Kidney Dis.201974568269510.1053/j.ajkd.2019.03.42731227226
     [Google Scholar]
  70. VaidyaA. MulateroP. BaudrandR. AdlerG.K. The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment.Endocr. Rev.20183961057108810.1210/er.2018‑0013930124805
     [Google Scholar]
  71. HundemerG.L. SoodM.M. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management.Pharmacol. Res.202117210583510.1016/j.phrs.2021.10583534438065
     [Google Scholar]
  72. WhitlockR. LeonS.J. ManacsaH. AskinN. RigattoC. FatobaS.T. FaragY.M.K. TangriN. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: A systematic review and meta-analysis.Nephrol. Dial. Transplant.202338112503251610.1093/ndt/gfad10137309038
     [Google Scholar]
  73. PalmerB.F. CleggD.J. Extrarenal effects of aldosterone on potassium homeostasis.Kidney36020223356156810.34067/KID.000676202135582177
     [Google Scholar]
  74. AshjianE. ClarkeM. PogueK. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes.Am. J. Health Syst. Pharm.202380231708172110.1093/ajhp/zxad19237632460
     [Google Scholar]
  75. JiangX. ZhangZ. LiC. ZhangS. SuQ. YangS. LiuX. HuY. PuX. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: A systematic review incorporating an indirect comparisons meta-analysis.Front. Pharmacol.20221389694710.3389/fphar.2022.89694735784710
     [Google Scholar]
  76. GoldmanJ.D. Optimizing finerenone in people with diabetes and chronic kidney disease: an opportunity for the pharmacist.J. Pharm. Pract.20240897190024125672510.1177/0897190024125672538807033
     [Google Scholar]
  77. DunnJ.D. BentonW.W. Orozco-TorrenteraE. AdamsonR.T. The burden of hyperkalemia in patients with cardiovascular and renal disease.Am. J. Manag. Care20152115Suppl.s307s31526788745
     [Google Scholar]
  78. RossignolP. LegrandM. KosiborodM. HollenbergS.M. PeacockW.F. EmmettM. EpsteinM. KovesdyC.P. YilmazM.B. StoughW.G. GayatE. PittB. ZannadF. MebazaaA. Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future.Pharmacol. Res.2016113Pt A58559110.1016/j.phrs.2016.09.03927693804
     [Google Scholar]
  79. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.Kidney Int.20221025SS1S12736272764
     [Google Scholar]
  80. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2022.Diabetes Care202245Suppl. 1S125S14310.2337/dc22‑S00934964831
     [Google Scholar]
  81. ManciaG. KreutzR. BrunströmM. BurnierM. GrassiG. JanuszewiczA. MuiesanM.L. TsioufisK. Agabiti-RoseiE. AlgharablyE.A.E. AziziM. BenetosA. BorghiC. HitijJ.B. CifkovaR. CocaA. CornelissenV. CruickshankJ.K. CunhaP.G. DanserA.H.J. PinhoR.M. DellesC. DominiczakA.F. DorobantuM. DoumasM. Fernández-AlfonsoM.S. HalimiJ.M. JáraiZ. JelakovićB. JordanJ. KuznetsovaT. LaurentS. LovicD. LurbeE. MahfoudF. ManolisA. MiglinasM. NarkiewiczK. NiiranenT. PalatiniP. ParatiG. PathakA. PersuA. PoloniaJ. RedonJ. SarafidisP. SchmiederR. SpronckB. StabouliS. StergiouG. TaddeiS. ThomopoulosC. TomaszewskiM. Van de BorneP. WannerC. WeberT. WilliamsB. ZhangZ.Y. KjeldsenS.E. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension.J. Hypertens.202341121874207110.1097/HJH.000000000000348037345492
     [Google Scholar]
  82. SarafidisP. IatridiF. FerroC. AlexandrouM.E. Fernandez-FernandezB. KanbayM. MallamaciF. NistorI. RossignolP. WannerC. CozzolinoM. OrtizA. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA).Clin. Kidney J.202316111885190710.1093/ckj/sfad13937915899
     [Google Scholar]
  83. MarxN. FedericiM. SchüttK. Müller-WielandD. AjjanR.A. AntunesM.J. ChristodorescuR.M. CrawfordC. Di AngelantonioE. EliassonB. Espinola-KleinC. FauchierL. HalleM. HerringtonW.G. Kautzky-WillerA. LambrinouE. LesiakM. LettinoM. McGuireD.K. MullensW. RoccaB. SattarN. PrescottE. CosentinoF. AbdelhamidM. AboyansV. AntoniouS. AsteggianoR. BaumgartnerI. BuccheriS. BuenoH. ČelutkienėJ. ChieffoA. ChristerssonC. CoatsA. CosynsB. CzernyM. DeatonC. FalkV. FerenceB.A. FilippatosG. FisherM. HuikuriH. IbanezB. JaarsmaT. JamesS. KhuntiK. KøberL. KoskinasK.C. LewisB.S. LøchenM-L. McEvoyJ.W. MihaylovaB. MindhamR. NeubeckL. NielsenJ.C. ParatiG. PasquetA.A. PatronoC. PetersenS.E. PiepoliM.F. RakishevaA. RosselloX. RossingP. RydénL. StandlE. TokgozogluL. TouyzR.M. VisserenF. VolpeM. VrintsC. WitkowskiA. HazarapetyanL. ZirlikA. RustamovaY. van de BorneP. SokolovićŠ. GotchevaN. MilicicD. AgathangelouP. VrablíkM. SchouM. Hasan-AliH. ViigimaaM. LautamäkiR. AboyansV. KlimiashviliZ. KelmM. SiasosG. KissR.G. LibunganB. DurkanM. ZafrirB. ColivicchiF. TundybayevaM. BytyçiI. MirrakhimovE. TrusinskisK. SaadéG. BadarienėJ. BanuC-A. MagriC.J. BoskovicA. HattaouiM.E. MartensF. BosevskiM. KnudsenE.C. BurchardtP. Fontes-CarvalhoR. VinereanuD. ManciniT. BeleslinB. MartinkaE. FrasZ. CondeA.C. MellbinL. CarballoD. BsataW. MghaiethF. GungorB. MitchenkoO. WheatcroftS. TrigulovaR. PrescottE. JamesS. ArbeloE. BaigentC. BorgerM.A. BuccheriS. IbanezB. KøberL. KoskinasK.C. McEvoyJ.W. MihaylovaB. MindhamR. NeubeckL. NielsenJ.C. PasquetA.A. RakishevaA. RoccaB. RossellóX. VaartjesI. VrintsC. WitkowskiA. ZeppenfeldK. ESC Scientific Document Group 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.Eur. Heart J.202344394043414010.1093/eurheartj/ehad19237622663
     [Google Scholar]
  84. ItoS. KashiharaN. ShikataK. NangakuM. WadaT. OkudaY. SawanoboriT. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): Phase 3 randomized controlled clinical trial.Clin. J. Am. Soc. Nephrol.202015121715172710.2215/CJN.0687052033239409
     [Google Scholar]
  85. WadaT. InagakiM. YoshinariT. TerataR. TotsukaN. GotouM. HashimotoG. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.Clin. Exp. Nephrol.202125212013010.1007/s10157‑020‑01963‑z32974732
     [Google Scholar]
  86. BakrisG. PergolaP.E. DelgadoB. GenovD. DoliashviliT. VoN. YangY.F. McCabeJ. BennV. PittB. BLOCK-CKD Study Group Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the block-ckd study.Hypertension2021781748110.1161/HYPERTENSIONAHA.121.1707333966452
     [Google Scholar]
  87. SquireI.B. GabrielsenA. GreasleyP.J. WernevikL. Hartleib-GeschwindnerJ. HoldenJ. JohanssonS. RudvikA. SánchezJ. BambergK. MelinJ. WhittakerA. Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.Clin. Transl. Sci.202215102493250410.1111/cts.1337735971596
     [Google Scholar]
  88. MarxN. HusainM. LehrkeM. VermaS. SattarN. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes.Circulation2022146241882189410.1161/CIRCULATIONAHA.122.05959536508493
     [Google Scholar]
  89. SattarN. LeeM.M.Y. KristensenS.L. BranchK.R.H. Del PratoS. KhurmiN.S. LamC.S.P. LopesR.D. McMurrayJ.J.V. PratleyR.E. RosenstockJ. GersteinH.C. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.Lancet Diabetes Endocrinol.202191065366210.1016/S2213‑8587(21)00203‑534425083
     [Google Scholar]
  90. GiuglianoD. LongoM. SignorielloS. MaiorinoM.I. SolerteB. ChiodiniP. EspositoK. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.Cardiovasc. Diabetol.20222114210.1186/s12933‑022‑01474‑z35296336
     [Google Scholar]
  91. GiuglianoD. MaiorinoM.I. BellastellaG. EspositoK. The residual cardiorenal risk in type 2 diabetes.Cardiovasc. Diabetol.20212013610.1186/s12933‑021‑01229‑233546683
     [Google Scholar]
  92. Di LulloL. LavalleC. ScatenaA. MarianiM.V. RoncoC. BellasiA. Finerenone: Questions and answers-the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist.J. Clin. Med.202312123992
     [Google Scholar]
  93. MårupF.H. ThomsenM.B. BirnH. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial.Clin. Kidney J.2024171sfad24910.1093/ckj/sfad24938186886
     [Google Scholar]
  94. ProvenzanoM. PuchadesM.J. GarofaloC. JongsN. D’MarcoL. AndreucciM. De NicolaL. GorrizJ.L. HeerspinkH.J.L. ROTATE-3 study group ROTATE-3 study group members Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: A randomized crossover clinical trial.J. Am. Soc. Nephrol.20223381569158010.1681/ASN.202202020735440501
     [Google Scholar]
  95. HeerspinkH.J.L. AgarwalR. BakrisG.L. CherneyD.Z.I. LamC.S.P. NeuenB.L. SarafidisP.A. TuttleK.R. WannerC. BrinkerM.D. DizayeeS. KolkhofP. SchloemerP. VesterinenP. PerkovicV. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.Nephrol. Dial. Transplant.202416351852410.1093/ndt/gfae13238858818
     [Google Scholar]
  96. GreenJ.B. MottlA.K. BakrisG. HeerspinkH.J.L. MannJ.F.E. McGillJ.B. NangakuM. RossingP. ScottC. GayA. AgarwalR. Design of the combinatioN effect of fInerenone anD empaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE).Nephrol. Dial. Transplant.202338489490310.1093/ndt/gfac19835700142
     [Google Scholar]
  97. DesaiN.R. NavaneethanS.D. NicholasS.B. PantaloneK.M. WannerC. HamacherS. GayA. WheelerD.C. Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice.J. Diabetes Complications202337410841110.1016/j.jdiacomp.2023.10841136857997
     [Google Scholar]
  98. HeerspinkH.J.L. BirkenfeldA.L. CherneyD.Z.I. ColhounH.M. JiL. MathieuC. GroopP.H. PratleyR.E. RosasS.E. RossingP. SkylerJ.S. TuttleK.R. LawatscheckR. ScottC. EdforsR. ScheererM.F. KolkhofP. McGillJ.B. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.Diabetes Res. Clin. Pract.202320411090810.1016/j.diabres.2023.11090837805000
     [Google Scholar]
  99. SchaeferF. MontiniG. KangH.G. WalleJ. Vande ZaritskyJ. SchreuderM.F. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.Trials202425120310.1186/s13063‑024‑08021‑z
     [Google Scholar]
  100. The effect of finerenone in kidney transplantion recipients: The EFFEKTOR study.NCT060596642024
  101. SolomonS.D. OstrominskiJ.W. VaduganathanM. ClaggettB. JhundP.S. DesaiA.S. LamC.S.P. PittB. SenniM. ShahS.J. VoorsA.A. ZannadF. AbidinI.Z. Alcocer-GambaM.A. AthertonJ.J. BauersachsJ. MaC.S. ChiangC.E. ChioncelO. ChopraV. Comin-ColetJ. FilippatosG. FonsecaC. GajosG. GolandS. GoncalvesováE. KangS.M. KatovaT. KosiborodM.N. LatkovskisG. LeeA.P.W. LinssenG.C.M. Llamas-EsperónG. MareevV. MartinezF.A. MelenovskýV. MerkelyB. NodariS. PetrieM.C. SaldarriagaC.I. SaraivaJ.F.K. SatoN. SchouM. SharmaK. TroughtonR. UdellJ.A. UkkonenH. VardenyO. VermaS. von LewinskiD. VoronkovL.G. YilmazM.B. ZierothS. Lay-FlurrieJ. van GamerenI. AmaranteF. ViswanathanP. McMurrayJ.J.V. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.Eur. J. Heart Fail.20242661334134610.1002/ejhf.326638733212
     [Google Scholar]
  102. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF).NCT060081972024
  103. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) (CONFIRMATION).NCT060247462024
  104. A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF).NCT060339502024
/content/journals/emiddt/10.2174/0118715303350851241021105850
Loading
Improving Renal Protection in Chronic Kidney Disease Associated with Type 2 Diabetes: The Role of Finerenone
Endocr Metab Immune Disord Drug Targets 25, 1133 (2025); https://doi.org/10.2174/0118715303350851241021105850
/content/journals/emiddt/10.2174/0118715303350851241021105850
/content/journals/emiddt/10.2174/0118715303350851241021105850
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Chronic kidney disease; diabetic kidney disease; finerenone; kidney replacement therapy; nonsteroidal mineralocorticoid receptor antagonists; type 2 diabetes mellitus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test